MetaCap

Alvotech (ALVO) vs Replimune Group (REPL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Replimune Group (REPL) has outperformed Alvotech (ALVO) over the past year, gaining 107.3% versus a loss of 19.8%. Replimune Group is the larger company by market cap ($1.81 billion vs $1.47 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-19.84%REPL+107.28%
+165%+36%-93%
Nov 21, 20251 yearNov 20, 2026
ALVO-57.53%REPL+25.46%
+95%+0%-94%
Jun 13, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus REPL key metrics
MetricALVOREPL
Share price$4.12$19.07
Market cap$1.47B$1.81B
1-day change-3.96%-0.83%
YTD return-19.69%+96.19%
1-year return-19.84%+107.28%
5-year return—-34.24%
Forward P/E19.46—
EPS (TTM)$-0.82$-2.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M$-313.94M
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$23.54
52-week low$2.94$1.50
Distance from 52-week high-36.91%-18.99%
Analyst consensusbuybuy
Avg. price target upside+82.04%+33.72%
Average volume1.13M2.48M
Shares outstanding356.82M94.80M
Employees1,279465
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • REPL has outperformed ALVO by 127.1 percentage points over the past year.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Replimune Group

REPL stock →

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees

ALVO vs REPL FAQ

Which is bigger, Alvotech or Replimune Group?

Replimune Group (REPL) is larger, with a market capitalization of $1.81B compared with $1.47B for Alvotech (ALVO).

Which stock has performed better over the past year, ALVO or REPL?

REPL returned +107.28% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.

Are Alvotech and Replimune Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons